UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
OR 15(d) of
The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported) October 22, 2008
| AspenBio Pharma, Inc. | |
| (Exact name of registrant as specified in charter) |
| Colorado | 001-33675 | 84-155338 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 1585 South Perry Street, Castle Rock, CO | 80104 |
|---|---|
| (Address of principal executive offices) | (Zip Code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
The power point presentation information furnished on Exhibit 99.2 is hereby incorporated by reference under this Item 7.01 as if fully set forth herein and is available on the Company’s website.
On October 22, 2008, the Registrant issued a press release titled; “AspenBio Pharma Reports on FDA 510(k) Clinical Trial Progress for AppyScore, World’s First Blood-Based Diagnostic Test for Human Appendicitis”. A copy of this press release is attached hereto as Exhibit 99.1.
| Exhibit No |
Description |
| 99.1 | Press release dated October 22, 2008 titled, “AspenBio Pharma Reports on FDA 510(k) Clinical Trial Progress for AppyScore, World’s First Blood-Based Diagnostic Test for Human Appendicitis” |
| 99.2 | Company information - "Power Point Presentation" dated October 2008 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AspenBio Pharma, Inc. (Registrant) |
||
|---|---|---|
| Date: October 22, 2008 | By: | /s/ Jeffrey G. McGonegal |
| Jeffrey G. McGonegal | ||
| Chief Financial Officer |